Effect of the Synthetic Bile Salt Analog CamSA on the Hamster Model of Clostridium difficile Infection

Antimicrobial Agents and Chemotherapy
Amber HowertonErnesto Abel-Santos

Abstract

Clostridium difficile infection (CDI) is the leading cause of antibiotic-associated diarrhea and has gained worldwide notoriety due to emerging hypervirulent strains and the high incidence of recurrence. We previously reported protection of mice from CDI using the antigerminant bile salt analog CamSA. Here we describe the effects of CamSA in the hamster model of CDI. CamSA treatment of hamsters showed no toxicity and did not affect the richness or diversity of gut microbiota; however, minor changes in community composition were observed. Treatment of C. difficile-challenged hamsters with CamSA doubled the mean time to death, compared to control hamsters. However, CamSA alone was insufficient to prevent CDI in hamsters. CamSA in conjunction with suboptimal concentrations of vancomycin led to complete protection from CDI in 70% of animals. Protected animals remained disease-free at least 30 days postchallenge and showed no signs of colonic tissue damage. In a delayed-treatment model of hamster CDI, CamSA was unable to prevent infection signs and death. These data support a putative model in which CamSA reduces the number of germinating C. difficile spores but does not keep all of the spores from germinating. Vancomycin halts divi...Continue Reading

References

Jul 18, 1977·Research in Experimental Medicine. Zeitschrift Für Die Gesamte Experimentelle Medizin Einschliesslich Experimenteller Chirurgie·S V Rana
Oct 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J G Bartlett
Jun 1, 1991·Antimicrobial Agents and Chemotherapy·R N SwansonJ J Clement
Jul 1, 1987·Antimicrobial Agents and Chemotherapy·M Y DongS L Gorbach
Feb 1, 1985·Infection and Immunity·D M LyerlyT D Wilkins
Apr 2, 1998·The Journal of Hospital Infection·M H WilcoxA Davidson
Feb 24, 2001·American Journal of Physiology. Gastrointestinal and Liver Physiology·C Pothoulakis, J T Lamont
Feb 19, 2002·Letters in Applied Microbiology·T HamoudaJ R Baker
May 23, 2002·Antimicrobial Agents and Chemotherapy·T PeláezE Bouza
Aug 2, 2003·Gastroenterology·Tor C SavidgeCharalabos Pothoulakis
Sep 25, 2004·Antimicrobial Agents and Chemotherapy·Pauline M AntonCharalabos Pothoulakis
Oct 11, 2007·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Judith A O'BrienDavid M Davidson
Feb 5, 2008·Journal of Bacteriology·Joseph A Sorg, Abraham L Sonenshein
May 16, 2008·Journal of Medical Microbiology·Patrizia Spigaglia On Behalf Of The European Study Group On Clostridium Difficile Esgcd
Oct 14, 2008·Gastroenterology·Xinhua ChenCiarán P Kelly
Nov 26, 2009·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·M J T CrobachE J Kuijper
Mar 24, 2010·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Stuart H CohenUNKNOWN Infectious Diseases Society of America
Apr 13, 2010·Nature Methods·J Gregory CaporasoRob Knight
Jun 22, 2010·Journal of Bacteriology·Norma RamirezErnesto Abel-Santos
Jul 3, 2010·Methods in Molecular Biology·Gillian Douce, David Goulding
Oct 26, 2010·Journal of Bacteriology·Amber HowertonErnesto Abel-Santos
Feb 19, 2011·Journal of Medical Microbiology·Anthony M BuckleyGillian R Douce
Apr 20, 2011·Nature Reviews. Gastroenterology & Hepatology·Christina M Surawicz, Jacob Alexander
May 18, 2011·Infection and Immunity·Xingmin SunHanping Feng
Mar 23, 2012·The ISME Journal·Clara Belzer, Willem M de Vos
Jun 27, 2012·Antimicrobial Agents and Chemotherapy·Michelle M ButlerTerry L Bowlin
Jan 19, 2013·Molecular Biology and Evolution·Kazutaka Katoh, Daron M Standley
Feb 20, 2013·The Journal of Infectious Diseases·Amber HowertonErnesto Abel-Santos
Feb 27, 2013·The American Journal of Gastroenterology·Christina M SurawiczBrian S Zuckerbraun
Sep 12, 2013·PloS One·Amber HowertonErnesto Abel-Santos
Oct 15, 2013·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·S B DebastUNKNOWN European Society of Clinical Microbiology and Infectious Diseases

❮ Previous
Next ❯

Citations

Nov 6, 2020·Biochemical Pharmacology·Christopher YipErnesto Abel-Santos
Nov 19, 2021·Expert Opinion on Therapeutic Targets·Tanya M MonaghanWeng C Chan
Nov 16, 2021·Antimicrobial Agents and Chemotherapy·Jacqueline R PhanErnesto Abel-Santos

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.